A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer
Several immune checkpoint inhibitors targeting the PD-1 pathway have been developed with clinical trials showing an approximately 20% durable response in unselected patients with advanced non-small cell lung cancer (NSCLC). At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 tumor responsiveness. The goal of this study is to broadly discover and evaluate the utility of blood based biomarkers for use in measuring and predicting response to immunotherapy in patients with lung cancer.
Checked against the public recordLast updated Apr 19, 2021 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Interventions being studied
- Other: Blood and Urine Collection
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Advanced Metastatic NSCLC * Scheduled to initiate an immune checkpoint inhibitor * Age \>= 18 years * Able to provide informed consent Exclusion Criteria: * Other, unrelated, concomitant active, invasive malignancy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 19, 2021. Always confirm current availability with the study team.